title: Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes.
abstract: The objective of this study was to determine the prevalence, mutual associations, clinical manifestations, and diagnoses associated with serum autoantibodies, as detected using recently available immunoassays, in patients with autoimmune myositis (AIM). Sera and clinical data were collected from 100 patients with AIM followed longitudinally. Sera were screened cross-sectionally for 21 autoantibodies by multiplex addressable laser bead immunoassay, line blot immunoassay, immunoprecipitation of in vitro translated recombinant protein, protein A assisted immunoprecipitation, and enzyme-linked immunosorbent assay. Diagnoses were determined using the Bohan and Peter classification as well as recently proposed classifications. Relationships between autoantibodies and clinical manifestations were analyzed by multiple logistic regression. One or more autoantibodies encompassing 19 specificities were present in 80% of the patients. The most common autoantibodies were anti-Ro52 (30% of patients), anti-Ku (23%), anti-synthetases (22%), anti-U1RNP (15%), and anti-fibrillarin (14%). In the presence of autoantibodies to Ku, synthetases, U1RNP, fibrillarin, PM-Scl, or scleroderma autoantigens, at least one more autoantibody was detected in the majority of sera and at least two more autoantibodies in over one-third of sera. The largest number of concurrent autoantibodies was six autoantibodies. Overall, 44 distinct combinations of autoantibodies were counted. Most autoantibodies were unrestricted to any AIM diagnostic category. Distinct clinical syndromes and therapeutic responses were associated with anti-Jo-1, anti-fibrillarin, anti-U1RNP, anti-Ro, anti-Ro52, and autoantibodies to scleroderma autoantigens. We conclude that a significant proportion of AIM patients are characterized by complex associations of autoantibodies. Certain myositis autoantibodies are markers for distinct overlap syndromes and predict therapeutic outcomes. The ultimate clinical features, disease course, and response to therapy in a given AIM patient may be linked to the particular set of associated autoantibodies. These results provide a rationale for patient profiling and its application to therapeutics, because it cannot be assumed that the B-cell response is the same even in the majority of patients in a given diagnostic category.
authors: University of Montreal School of Medicine, and Laboratory for Research in Autoimmunity, Centre Hospitalier de l'Université de Montréal, M-4243, 1560 East Sherbrooke Street, Montreal, Quebec, Canada H2L 4M1.
authors: Martial
authors: M
authors: Koenig
authors: Marvin J
authors: MJ
authors: Fritzler
authors: Ira N
authors: IN
authors: Targoff
authors: Yves
authors: Y
authors: Troyanov
authors: Jean-Luc
authors: JL
authors: Senécal
mesh_terms: D000293:Adolescent; D000328:Adult; D000974:Antibodies, Antinuclear / Q000097:blood*; D001324:Autoantigens / Q000276:immunology*; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000276:immunology*; D003430:Cross-Sectional Studies; D018604:Epitope Mapping; D000939:Epitopes / Q000276:immunology*; D006801:Humans; D007118:Immunoassay; D009220:Myositis / Q000175:diagnosis / Q000276:immunology*
chemical_list: D000974:Antibodies, Antinuclear; D001324:Autoantigens; D000939:Epitopes
references: J Immunol Methods. 2000 Sep 21;243(1-2):243-55
references: 10986418
references: Neurology. 2003 Aug 12;61(3):288-9
references: 12913184
references: Rheumatology (Oxford). 2001 Oct;40(10):1157-62
references: 11600746
references: Arthritis Rheum. 2001 Oct;44(10):2367-70
references: 11665978
references: Medicine (Baltimore). 2002 Mar;81(2):154-67
references: 11889414
references: Semin Neurol. 2002 Mar;22(1):41-51
references: 12170392
references: Rheum Dis Clin North Am. 2002 Nov;28(4):859-90, viii
references: 12506776
references: Arthritis Rheum. 2003 Jan;48(1):203-9
references: 12528120
references: Arthritis Rheum. 2003 Jan;48(1):210-7
references: 12528121
references: Neurology. 2003 Aug 12;61(3):316-21
references: 12913190
references: Lancet. 2003 Nov 22;362(9397):1762-3; author reply 1763
references: 14643132
references: J Mol Med (Berl). 2003 Dec;81(12):811-8
references: 14598044
references: Arthritis Rheum. 2004 Oct;50(10):3265-74
references: 15476238
references: N Engl J Med. 1975 Feb 20;292(8):403-7
references: 1089199
references: N Engl J Med. 1975 Feb 13;292(7):344-7
references: 1090839
references: Arthritis Rheum. 1984 Oct;27(10):1150-6
references: 6386003
references: Arthritis Rheum. 1985 Jul;28(7):796-803
references: 2409985
references: Arthritis Rheum. 1988 Oct;31(10):1322-7
references: 3052460
references: Clin Exp Immunol. 1989 Jun;76(3):366-72
references: 2665976
references: J Immunol. 1990 Mar 1;144(5):1737-43
references: 2307838
references: Arthritis Rheum. 1990 Sep;33(9):1361-70
references: 2403400
references: Medicine (Baltimore). 1991 Nov;70(6):360-74
references: 1659647
references: Arthritis Rheum. 1992 Jan;35(1):95-100
references: 1731817
references: Arthritis Rheum. 1992 Apr;35(4):449-56
references: 1567494
references: Medicine (Baltimore). 1992 Nov;71(6):327-36
references: 1435228
references: J Clin Invest. 1993 Jun;91(6):2556-64
references: 8514867
references: Arthritis Rheum. 1993 Aug;36(8):1121-7
references: 8343187
references: J Cell Biol. 1993 Dec;123(6 Pt 1):1345-54
references: 8253835
references: Arthritis Rheum. 1994 Feb;37(2):248-52
references: 8129780
references: J Immunol. 1995 Jan 15;154(2):961-71
references: 7529293
references: J Rheumatol. 1995 Apr;22(4):581-5
references: 7791146
references: J Clin Invest. 1995 Oct;96(4):1730-7
references: 7560064
references: Br J Rheumatol. 1996 Apr;35(4):305-6
references: 8624632
references: Arthritis Rheum. 1996 Jul;39(7):1151-60
references: 8670324
references: Clin Immunol Immunopathol. 1996 Oct;81(1):41-7
references: 8808640
references: Arthritis Rheum. 1996 Sep;39(9):1507-18
references: 8814062
references: Arthritis Rheum. 1997 Jul;40(7):1257-66
references: 9214426
references: Clin Exp Immunol. 1997 Jul;109(1):32-40
references: 9218821
references: Curr Opin Rheumatol. 1997 Nov;9(6):527-35
references: 9375282
references: J Rheumatol. 1999 Mar;26(3):563-7
references: 10090163
references: Arthritis Rheum. 1999 May;42(5):899-909
references: 10323445
references: Reumatismo. 2005 Jan-Mar;57(1):22-8
references: 15776143
references: Medicine (Baltimore). 2005 Jul;84(4):231-49
references: 16010208
references: Arthritis Rheum. 2005 Aug;52(8):2425-32
references: 16052583
references: Semin Arthritis Rheum. 2005 Aug;35(1):35-42
references: 16084222
references: Ann Rheum Dis. 2006 Feb;65(2):242-5
references: 16410528
references: Autoimmunity. 2006 May;39(3):217-21
references: 16769655
references: Lupus. 2006;15(7):422-7
references: 16898176
references: Clin Immunol. 2006 Sep;120(3):349-56
references: 16644287
references: Ann Rheum Dis. 2001 Feb;60(2):116-23
references: 11156543